|
ES2059571T3
(es)
|
1988-01-19 |
1994-11-16 |
Takeda Chemical Industries Ltd |
Fumagilina como agente angiostatico.
|
|
CA1329771C
(en)
|
1988-09-01 |
1994-05-24 |
Shoji Kishimoto |
Angiogenesis inhibitory agent
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
CA2647545C
(en)
|
2006-04-03 |
2016-02-23 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
|
|
JP4611444B2
(ja)
|
2007-01-10 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
EP2217244A4
(en)
|
2007-11-12 |
2011-08-31 |
Bipar Sciences Inc |
TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES
|
|
US7732491B2
(en)
|
2007-11-12 |
2010-06-08 |
Bipar Sciences, Inc. |
Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
|
|
WO2009087474A2
(en)
|
2008-01-08 |
2009-07-16 |
Akthelia Pharmaceuticals |
Agonists for antimicrobial peptide systems
|
|
KR101653548B1
(ko)
|
2008-01-08 |
2016-09-02 |
머크 샤프 앤드 돔 리미티드 |
2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
CN102307475A
(zh)
*
|
2009-02-04 |
2012-01-04 |
彼帕科学公司 |
用与生长因子抑制剂组合的parp抑制剂治疗肺癌
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
WO2011153383A1
(en)
|
2010-06-04 |
2011-12-08 |
Bipar Science, Inc. |
Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
|
|
EP3012329B1
(en)
|
2010-06-18 |
2017-10-25 |
Myriad Genetics, Inc. |
Methods and materials for assessing loss of heterozygosity
|
|
WO2012027224A1
(en)
|
2010-08-24 |
2012-03-01 |
Dana-Farber Cancer Institute, Inc. |
Methods for predicting anti-cancer response
|
|
CA2742342A1
(en)
|
2011-02-12 |
2012-08-12 |
Baylor Research Institute |
Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
WO2013182645A1
(en)
|
2012-06-07 |
2013-12-12 |
Institut Curie |
Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
|
|
EP2928473B1
(en)
|
2012-12-07 |
2017-06-28 |
Merck Sharp & Dohme Corp. |
Regioselective n-2 arylation of indazoles
|
|
US9738915B2
(en)
|
2012-12-07 |
2017-08-22 |
Merck Sharp & Dohme Corp. |
Biocatalytic transamination process
|
|
US9850542B2
(en)
|
2013-03-04 |
2017-12-26 |
Board Of Regents, The University Of Texas System |
Gene signature to predict homologous recombination (HR) deficient cancer
|
|
US20150071910A1
(en)
|
2013-03-15 |
2015-03-12 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
|
SMT202100065T1
(it)
|
2013-05-02 |
2021-03-15 |
Anaptysbio Inc |
Anticorpi diretti contro la proteina della morte programmata (pd-1)
|
|
WO2015086473A1
(en)
|
2013-12-09 |
2015-06-18 |
Institut Curie |
Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
|
|
CN105917007A
(zh)
|
2014-01-16 |
2016-08-31 |
克洛维斯肿瘤有限公司 |
Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途
|
|
WO2015116868A2
(en)
*
|
2014-01-29 |
2015-08-06 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
WO2015184145A1
(en)
|
2014-05-28 |
2015-12-03 |
Eisai R&D Management Co., Ltd. |
Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
|
|
US20150344968A1
(en)
|
2014-05-30 |
2015-12-03 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Methods for determining parp inhibitor and platinum resistance in cancer therapy
|
|
US20160160294A1
(en)
|
2014-12-08 |
2016-06-09 |
Tesaro |
Methods and materials for predicting response to niraparib
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
FI3277321T3
(fi)
|
2015-04-01 |
2024-10-31 |
Anaptysbio Inc |
T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
|
|
JP2018514550A
(ja)
|
2015-04-28 |
2018-06-07 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
|
|
MX2017015937A
(es)
|
2015-06-08 |
2018-12-11 |
Genentech Inc |
Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
|
|
JP6980980B2
(ja)
|
2015-06-25 |
2021-12-15 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
|
|
JP7042739B2
(ja)
|
2015-08-20 |
2022-03-28 |
イプセン バイオファーム リミティド |
癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
|
|
SG11201803462PA
(en)
|
2015-10-26 |
2018-05-30 |
Medivation Tech Llc |
Treatment of small cell lung cancer with a parp inhibitor
|
|
US20210322415A1
(en)
|
2016-02-15 |
2021-10-21 |
Astrazeneca Ab |
Methods comprising fixed intermittent dosing of cediranib
|
|
SG11201811564QA
(en)
|
2016-06-29 |
2019-01-30 |
Tesaro Inc |
Methods of treating ovarian cancer
|
|
CN110087730B
(zh)
*
|
2016-09-27 |
2023-03-28 |
百济神州(苏州)生物科技有限公司 |
使用包含parp抑制剂的组合产品治疗癌症
|
|
MX2019005116A
(es)
|
2016-11-01 |
2019-11-12 |
Anaptysbio Inc |
Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
|
|
JP2019533458A
(ja)
|
2016-11-01 |
2019-11-21 |
アナプティスバイオ インコーポレイティッド |
プログラム死１（ｐｄ−１）に対する抗体
|
|
AU2018206481B2
(en)
|
2017-01-09 |
2025-02-27 |
Tesaro, Inc. |
Methods of treating cancer with anti-PD-1 antibodies
|
|
WO2018129553A1
(en)
|
2017-01-09 |
2018-07-12 |
Tesaro, Inc. |
Methods of treating cancer with anti-tim-3 antibodies
|
|
KR20190130625A
(ko)
|
2017-03-27 |
2019-11-22 |
테사로, 인코포레이티드 |
니라파립 제제
|
|
CN110944638A
(zh)
|
2017-03-27 |
2020-03-31 |
特沙诺有限公司 |
尼拉帕尼组合物
|
|
MA48475A
(fr)
|
2017-04-24 |
2020-03-04 |
Tesaro Inc |
Procédés de fabrication de niraparib
|
|
SG11201909395TA
(en)
|
2017-04-27 |
2019-11-28 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
TW202444417A
(zh)
|
2017-05-09 |
2024-11-16 |
美商提薩羅有限公司 |
治療癌症的組合療法
|
|
KR20200005662A
(ko)
|
2017-05-18 |
2020-01-15 |
테사로, 인코포레이티드 |
암을 치료하기 위한 조합 요법
|
|
US20200129482A1
(en)
|
2017-06-26 |
2020-04-30 |
Abbvie Inc. |
Treatment of non-small cell lung cancer
|
|
TWI843707B
(zh)
|
2017-09-26 |
2024-06-01 |
美商提薩羅有限公司 |
尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
|
|
MX2020003770A
(es)
|
2017-09-30 |
2020-07-29 |
Tesaro Inc |
Terapias de combinacion para tratar cancer.
|
|
EA202090655A1
(ru)
|
2017-10-06 |
2020-12-07 |
Тесаро, Инк. |
Комбинированные терапевтические средства и их применение
|
|
US20210106574A1
(en)
|
2017-12-27 |
2021-04-15 |
Tesaro, Inc. |
Methods of Treating Cancer
|
|
CN111918667A
(zh)
|
2018-02-05 |
2020-11-10 |
特沙诺有限公司 |
儿科尼拉帕尼配制剂和儿科治疗方法
|
|
EA201992594A1
(ru)
|
2018-03-26 |
2020-03-20 |
Тесаро, Инк. |
Комбинированные терапии для лечения рака
|
|
US11970530B2
(en)
|
2020-08-13 |
2024-04-30 |
Astrazeneca Ab |
Methods of treating homologous recombination deficient cancer
|